Icon

COTELLIC (nda206192)- (EQ 20MG BASE)

COBIMETINIB FUMARATE GENENTECH INC
EQ 20MG BASE
No No
2036-Dec-30 2020-Nov-10
2022-Nov-10 None
None No
COTELLIC® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.
0 0 0
Total Other Developers 1
Drugs with Suitability No
EQ 20MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.